Nara, K., Yamamoto, T., Yamashita, H., Yagi, K., Takada, T., Seto, Y., & Suzuki, H. (2023). Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: A single center retrospective study. BMC.
Cytowanie według stylu Chicago (wyd. 17)Nara, Katsuhiko, Takehito Yamamoto, Hiroharu Yamashita, Koichi Yagi, Tappei Takada, Yasuyuki Seto, i Hiroshi Suzuki. Prior Treatment with Oxaliplatin-containing Regimens and Higher Total Bilirubin Levels Are Risk Factors for Neutropenia and Febrile Neutropenia in Patients with Gastric or Esophagogastric Junction Cancer Receiving Weekly Paclitaxel and Ramucirumab Therapy: A Single Center Retrospective Study. BMC, 2023.
Cytowanie według stylu MLA (wyd. 9)Nara, Katsuhiko, et al. Prior Treatment with Oxaliplatin-containing Regimens and Higher Total Bilirubin Levels Are Risk Factors for Neutropenia and Febrile Neutropenia in Patients with Gastric or Esophagogastric Junction Cancer Receiving Weekly Paclitaxel and Ramucirumab Therapy: A Single Center Retrospective Study. BMC, 2023.